Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of uniQure Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating uniQure N.V. on behalf of its stockholders due to potential legal claims related to federal securities law violations. This investigation follows uniQure's November 2025 press release, which revealed that the FDA does not consider data from their Phase I/II studies adequate for a BLA submission. Consequently, the company has stated that the timing for this submission is now uncertain, leading to a drastic drop in stock value. Investors affected by these developments are encouraged to contact the law firm for legal support.

Market Sentiment Analysis

CONCERNS & RISKS

  • uniQure's stock price fell over 57% following negative FDA feedback.
  • The uncertainty over the BLA submission timing raises investor concerns.
  • Investigation launched due to potential violations of federal securities laws.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in uniQure and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) on behalf of uniQure stockholders. Our investigation concerns whether uniQure has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
A press release issued by uniQure on November 3, 2025, discloses that the Company “believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.” The Company added, “Consequently, the timing of the BLA submission for AMT-130 is now unclear.” Based on this news, shares of uniQure fell by more than 57% in morning trading on the same day.
If you purchased or otherwise acquired uniQure shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

How can I discuss my legal rights with uniQure losses?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire directly.

What triggered the investigation into uniQure?

The investigation follows a press release about FDA concerns on AMT-130 data adequacy.

How much did uniQure shares drop after the FDA announcement?

Shares of uniQure fell over 57% in morning trading following the announcement.

What services does Bragar Eagel & Squire offer?

The firm represents investors in securities, derivative, and consumer protection litigation.

Is there a cost for contacting Bragar Eagel & Squire?

There is no cost or obligation for you to discuss potential claims.

Last updated: Jan 22, 2026